Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Phase 2 Completed
102 enrolled 12 charts
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Phase 1/2 Completed
5 enrolled 18 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Completed
33 enrolled 21 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Phase 1/2 Completed
21 enrolled 22 charts
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Phase 2 Completed
11 enrolled 12 charts
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase 1/2 Terminated
24 enrolled 18 charts
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase 2 Terminated
2 enrolled 8 charts
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase 2 Terminated
45 enrolled 15 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase 2 Terminated
24 enrolled 13 charts
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
6 enrolled 9 charts
Drosophila-generated CTL
Phase 2 Terminated
3 enrolled 8 charts
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
33 enrolled
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
34 enrolled 11 charts
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Phase 2 Terminated
3 enrolled 10 charts
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase 2 Terminated
3 enrolled 8 charts
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase 2 Completed
4 enrolled 11 charts
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Phase 1/2 Terminated
3 enrolled 8 charts
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
Phase 2 Terminated
58 enrolled
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Phase 2 Completed
158 enrolled 14 charts
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
Phase 1 Completed
20 enrolled
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Phase 2 Terminated
21 enrolled 11 charts
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Phase 2 Completed
24 enrolled 11 charts
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase 2 Completed
170 enrolled 23 charts
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Phase 2 Completed
8 enrolled 8 charts
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Phase 1/2 Terminated
1 enrolled 8 charts
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Phase 2 Completed
26 enrolled 11 charts
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 1 Completed
61 enrolled
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
Phase 1 Completed
136 enrolled
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
Phase 2 Completed
82 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled